Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2019 07:00 ET | Source: Trevena Inc.

Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain

CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...
March 04, 2019 07:00 ET | Source: Trevena Inc.

Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019

CHESTERBROOK, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
February 05, 2019 18:58 ET | Source: Trevena Inc.

Trevena to Present at the 21st Annual BIO CEO & Investor Conference

CHESTERBROOK, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options...
January 30, 2019 07:00 ET | Source: Trevena Inc.

Trevena Announces $10 Million Registered Direct Offering of Common Stock

CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused...
January 28, 2019 07:00 ET | Source: Trevena Inc.

Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine

– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
December 13, 2018 16:01 ET | Source: Trevena Inc.

National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology

CHESTERBROOK, Pa., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
December 10, 2018 07:00 ET | Source: Trevena Inc.

Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer

CHESTERBROOK, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment...
November 08, 2018 07:00 ET | Source: Trevena Inc.

Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring

– $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 – – Company to host conference call and webcast at 8:00am EST – CHESTERBROOK, Pa., Nov. 08, 2018 (GLOBE...
November 02, 2018 13:42 ET | Source: Trevena Inc.

Trevena Receives Complete Response Letter for Oliceridine from FDA

Company to host conference call and webcast on November 5th CHESTERBROOK, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced the Company has received a Complete...
October 12, 2018 16:01 ET | Source: Trevena Inc.

Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting

CHESTERBROOK, Pa., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN) today announced a poster presentation at ANESTHESIOLOGY® 2018, the national conference for the American Society of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right